HCR 103 expresses the Texas Legislature's support for the Texas Health and Human Services Commission’s (HHSC) application to participate in the Cell and Gene Therapy (CGT) Access Model under the federal Centers for Medicare and Medicaid Services (CMS). The resolution highlights the potential of cell and gene therapies to transform the treatment of rare and severe diseases by addressing their underlying causes, improving health outcomes, and potentially lowering long-term healthcare costs. The CGT Access Model, a voluntary initiative under CMS’s Center for Medicare and Medicaid Innovation, seeks to expand Medicaid beneficiaries’ access to these innovative treatments through state agreements with pharmaceutical manufacturers. These agreements would include negotiated pricing and outcomes-based payment models, reducing the financial burden on state Medicaid programs. By joining the CGT Access Model, Texas aims to explore innovative payment structures that could enhance care quality while managing costs.